Billionaire Cliff Asness’ 10 Stock Picks with Huge Upside Potential

2. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

AQR Capital Management’s Q4 Stake: $258.9 million

Upside Potential as of April 26: 45.64%

Number of Hedge Fund Holders: 57

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company that specializes in developing medicines for neurological, neuroendocrine, and neuropsychiatric illnesses. INGREZZA, the company’s flagship medicine, treats tardive dyskinesia and chorea in Huntington’s disease.The company additionally offers CRENESSITY, a first-in-class medication for congenital adrenal hyperplasia (CAH), and continues partnerships for treatments on endometriosis and uterine fibroids.

On April 28, Canaccord Genuity revised its financial outlook for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), lowering the stock’s price target from $163 to $158, while maintaining a Buy rating. Sumant Kulkarni, an analyst at Canaccord Genuity, stated that the revised model anticipates INGREZZA sales of $550 million, down from the prior estimate of $605 million. Despite this adjustment, Kulkarni noted that the expected sales for 2025 remain at $2.5 billion, which is consistent with Neurocrine Biosciences’ own predictions and represents a 9% increase over the estimated sales for 2024.